84 related articles for article (PubMed ID: 29686021)
1. Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer.
Saputra EC; Huang L; Chen Y; Tucker-Kellogg L
Cancer Res; 2018 May; 78(9):2419-2431. PubMed ID: 29686021
[TBL] [Abstract][Full Text] [Related]
2. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
[TBL] [Abstract][Full Text] [Related]
3. Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs.
Abd El-Hafeez T; Shams MY; Elshaier YAMM; Farghaly HM; Hassanien AE
Sci Rep; 2024 Jan; 14(1):2428. PubMed ID: 38287066
[TBL] [Abstract][Full Text] [Related]
4. Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs.
Tekin E; Beppler C; White C; Mao Z; Savage VM; Yeh PJ
J R Soc Interface; 2016 Jun; 13(119):. PubMed ID: 27278366
[TBL] [Abstract][Full Text] [Related]
5. Additivity predicts the efficacy of most approved combination therapies for advanced cancer.
Hwangbo H; Patterson SC; Dai A; Plana D; Palmer AC
Nat Cancer; 2023 Dec; 4(12):1693-1704. PubMed ID: 37974028
[TBL] [Abstract][Full Text] [Related]
6. The Evolution and Ecology of Resistance in Cancer Therapy.
Gatenby RA; Brown JS
Cold Spring Harb Perspect Med; 2020 Nov; 10(11):. PubMed ID: 33139405
[TBL] [Abstract][Full Text] [Related]
7. Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth.
Lacy MS; Jenner AL
Bull Math Biol; 2024 Mar; 86(4):43. PubMed ID: 38502371
[TBL] [Abstract][Full Text] [Related]
8. Modeling the impact of drug interactions on therapeutic selectivity.
Weinstein ZB; Kuru N; Kiriakov S; Palmer AC; Khalil AS; Clemons PA; Zaman MH; Roth FP; Cokol M
Nat Commun; 2018 Aug; 9(1):3452. PubMed ID: 30150706
[TBL] [Abstract][Full Text] [Related]
9. CISNE: An accurate description of dose-effect and synergism in combination therapies.
García-Fuente A; Vázquez F; Viéitez JM; García Alonso FJ; Martín JI; Ferrer J
Sci Rep; 2018 Mar; 8(1):4964. PubMed ID: 29563526
[TBL] [Abstract][Full Text] [Related]
10. Passenger mutations can accelerate tumour suppressor gene inactivation in cancer evolution.
Wodarz D; Newell AC; Komarova NL
J R Soc Interface; 2018 Jun; 15(143):. PubMed ID: 29875280
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer intratumour heterogeneity: current status and clinical implications.
Joseph C; Papadaki A; Althobiti M; Alsaleem M; Aleskandarany MA; Rakha EA
Histopathology; 2018 Nov; 73(5):717-731. PubMed ID: 29722058
[TBL] [Abstract][Full Text] [Related]
12. A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma.
Amjad E; Pezzani R; Sokouti B
Oncol Res; 2024; 32(3):439-461. PubMed ID: 38361756
[TBL] [Abstract][Full Text] [Related]
13. Interactions of plumbagin with five common antibiotics against Staphylococcus aureus in vitro.
Bie S; Mo Q; Shi C; Yuan H; Li C; Wu T; Li W; Yu H
PLoS One; 2024; 19(1):e0297493. PubMed ID: 38277418
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Drug Combinations Promote the Development of Resistance in Acute Myeloid Leukemia.
Mason-Osann E; Pomeroy AE; Palmer AC; Mettetal JT
Blood Cancer Discov; 2024 Mar; 5(2):95-105. PubMed ID: 38232314
[TBL] [Abstract][Full Text] [Related]
15. Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer.
Tan YQ; Chiou YS; Guo H; Zhang S; Huang X; Dukanya D; Kumar AM; Basappa S; Liu S; Zhu T; Basappa B; Pandey V; Lobie PE
NPJ Precis Oncol; 2024 Jan; 8(1):8. PubMed ID: 38200104
[TBL] [Abstract][Full Text] [Related]
16. Radionuclide Therapy of HER2-Expressing Xenografts Using [
Liu Y; Xu T; Vorobyeva A; Loftenius A; Bodenko V; Orlova A; Frejd FY; Tolmachev V
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173878
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the RIST Molecular-Targeted Regimen in a Three-Dimensional Neuroblastoma Spheroid Cell Culture Model.
Kaess C; Matthes M; Gross J; Waetzig R; Heise T; Corbacioglu S; Sommer G
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980635
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening reveals aprepitant to be a potent inhibitor of neutral sphingomyelinase 2: implications in blockade of exosome release in cancer therapy.
Moloudizargari M; Hekmatirad S; Gharaghani S; Moghadamnia AA; Najafzadehvarzi H; Asghari MH
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7207-7216. PubMed ID: 36884117
[TBL] [Abstract][Full Text] [Related]
19. Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy.
Meirelles LEF; Souza MVF; Carobeli LR; Morelli F; Mari NL; Damke E; Shinobu Mesquita CS; Teixeira JJV; Consolaro MEL; Silva VRSD
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830811
[TBL] [Abstract][Full Text] [Related]
20. screenwerk: a modular tool for the design and analysis of drug combination screens.
Hanes R; Ayuda-Durán P; Rønneberg L; Nakken S; Hovig E; Zucknick M; Enserink JM
Bioinformatics; 2023 Jan; 39(1):. PubMed ID: 36573326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
